INFANRIX-IPV+Hib is indicated for active immunisation against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b disease from the age of 2 months.
Baxalta Inc announced the publication of pivotal phase III data for BAX 111 (recombinant von Willebrand Factor) in Blood, the...
Primovist is indicated for the detection of focal liver lesions and provides information on the character of lesions in T1-weighted magnetic resonance imaging (MRI). Primovist should be used only when diagnostic information is essential and not available with unenhanced magnetic resonance imaging (MRI) and when delayed phase imaging is required. This medicinal product is for diagnostic use by intravenous administration only .
Mixed results from HEALOS Phase III trial of AM 111 to treat profound sudden deafness
Active immunization of infants from the age of 2 months and toddlers up to the age of 2 years for the prevention of invasive diseases caused by Haemophilus influenzae type b (Hib) and Neisseria meningitidis group C (MenC). See also section 4.4.
VBL Therapeutics announced the online publication of positive results of the pre-specified interim analysis of the OVAL study, a Phase III registration enabling study of VB 111 (ofranergene obadenovec) in recurrent platinum-resistant ovarian cancer.
Infanrix hexa is indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b. The use of Infanrix hexa should be in accordance with official recommendations.